The Blog

ROI from the LC/MS lab: challenges in a regulated environment

The popularity of mass spectrometry based testing is growing all the time. As a result, businesses in the diagnostics industry offering mass spectrometry based clinical assays, especially analytical laboratories in toxicology environments, are facing a number of major challenges. These include meeting scaling requirements that are non-linear, overcoming regulatory uncertainties while guaranteeing business continuity, raising ROI on LCMS instruments and lowering turnaround times.

So, if your business is offering mass spectrometry based tests, how do you make sure it continues to run smoothly and increase profitability for the long-term? In this short, powerful film, Rohit Shroff, Product Manager for Clinical Diagnostics in Tecan, offers a single, simple answer.

See what Rohit has to say now.